Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic ...

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic ...

– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –

Assembly broadens program into cholestatic liver diseases - BioTuesdays

Assembly Biosciences (NASDAQ: ASMB) has announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), broadening the program into cholestatic liver diseases. According to Assembly, ABI-6250 is currently being evaluated for chronic HDV infection and has completed a Phase 1a clinic…